We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 16 of 8728 for:    hypertension

Simvastatin in Patients With Isolated Arterial Hypertension (STIPPARE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01017835
Recruitment Status : Unknown
Verified November 2009 by Medical Universtity of Lodz.
Recruitment status was:  Recruiting
First Posted : November 23, 2009
Last Update Posted : November 23, 2009
Information provided by:
Medical Universtity of Lodz

Brief Summary:
The purpose of this study is to determine whether combined therapy with simvastatin and hypotensive drugs (ACEI or ARB) may decrease the blood pressure. Moreover, we would like to assess the influence of isolated hypertension on endothelial injury, and on the development of atherosclerosis.

Condition or disease

Detailed Description:
Hypertension is one of the most important predictors of cardiovascular diseases (CVD). Due to the fact that hypertension frequently coexists with hypercholesterolemia and diabetes which increase the risk of CVDs development, it is advisable to use the optimal combined therapy (hypotensive + hypolipidemic + hypoglycemic)in this group of patients. Statins are the most effective and widely used drugs for the treatment of hypercholesterolemia. According to the available experimental and clinical data they may decrease the blood pressure (BP) in normotensive and hypertensive patients. However, it is still difficult to determine to what degree the reduction of both blood pressure and cardiovascular risk is due to hypotensive or hypolipidemic/pleiotropic effects of statins.

Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Simvastatin in the Treatment of Isolated Arterial hyPertension and Prevention of cARdiovascular Events
Study Start Date : November 2009
Estimated Primary Completion Date : June 2011
Estimated Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Simvastatin
U.S. FDA Resources

statin treatment, isolated hypertension
treatment with statins, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
placebo treatment, isolated hypertension
treatment with placebo, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking

Biospecimen Retention:   Samples Without DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients hospitalized in the Department of Nephrology, Hypertension and Family Medicine,Clinical Hospital of Medical University of Lodz

Inclusion Criteria:

  • isolated hypertension (I or II class according to ESH guidelines 2009)

Exclusion Criteria:

  • ischemic heart disease, prior percutaneous coronary intervention (PCI), prior coronary artery bypass grafting (CABG), heart failure, diabetes, hyperlipidemia, active smokers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01017835

Contact: Marta Michalska, MSc 501154853 ext +48 michalska_marta84@wp.pl
Contact: Maciej Banach, MD PhD 604593040 ext +48 maciejbanach@aol.co.uk

Departament of Nephrology, Hypertension and Family Medicine, Clinical Hospital of Medical University of Lodz Recruiting
Lodz, Poland, 90-549
Sponsors and Collaborators
Medical Universtity of Lodz
Study Chair: Maciej Banach, MD PhD Departament of Hypertension , Medical University of Lodz

Responsible Party: Maciej Banach, Departament of Hypertension
ClinicalTrials.gov Identifier: NCT01017835     History of Changes
Other Study ID Numbers: 503-5139-2
First Posted: November 23, 2009    Key Record Dates
Last Update Posted: November 23, 2009
Last Verified: November 2009

Keywords provided by Medical Universtity of Lodz:
isolated hypertension
lipid profile

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors